Biotech News
Related news
ZURAZura Bio2026-08-31 20:30 EST
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NRIXNurix Therapeutics2026-08-20 11:00 EST
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
CUECue Biopharma Inc2026-08-03 12:30 EST
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
VERAVera Therapeutics2026-07-09 12:00 EST
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
STTKShattuck Labs2026-10-01 11:00 EST
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
TLSATiziana Life Sciences2026-08-06 11:00 EST
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
CUECue Biopharma Inc2026-07-13 12:30 EST
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
ARGXArgenx2026-09-17 20:03 EST
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-31 20:30 EST
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 4.14 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States